Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Cancer drugs

NICE adds two more drugs to cancer drugs fund

The National Institute for Health and Care Excellence (NICE) has made pembrolizumab (Keytruda) available for first-line use in lung cancer under the cancer drugs fund (CDF).

Olaratumab (Lartruvo), marketed by Eli Lilly, has also been added to the CDF for sarcoma.

Pembrolizumab is recommended for use for patients with untreated metastatic non-small-cell lung cancer whose tumours express PD-L1. Under the CDF guidance, eligible patients must have at least a 50% tumour proportion score, indicating high PD-L1 expression, and no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations.

The drug was approved for routine second-line use in lung cancer in December 2016, but rejected for first-line use by NICE in March.

Olaratumab is recommended under the CDF for use with doxorubicin in advanced sarcoma for patients who cannot be treated with surgery or radiotherapy. NICE called the extended survival of olaratumab-treated patients “unprecedented” — in trials, patients survived an additional 11.8 months, where the typical life expectancy is 12–16 months — but that the uncertainty over cost-effectiveness prevents them making it routinely available outside the CDF until more data are collected. 

Both manufacturers agreed to supply the drugs to the NHS at an undisclosed discount while more data are gathered. NICE say both drugs added to the CDF will be reviewed again as more data become available.

“With the changes that were made to the CDF, we are issuing guidance earlier than any other country in Europe,” says Carole Longson, director of the NICE Centre for Health Technology Evaluation. 

“With companies working closely with us and NHS England we will continue to deliver on our promise to give people fast access to the most effective cancer drugs,” she added.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203093

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now
  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • lung cancer carcinoma ss june 2017

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.